Revitalizing Indian Pharma: Charting a Resilient Path in the US Market

Embracing Transformation Amidst Challenges

The Indian pharmaceutical landscape embarked on a transformative journey, marked by challenges and strategic adaptations. The saga of Indian pharma's presence in the US market, once strong, saw turbulence in recent years. As we delve into the numbers and trends, a promising turnaround story begins to unfold.

1. A Glimpse into Recent Past

Dimming Lights in 2021 and 2022

The pandemic propelled Indian domestic pharma companies to the forefront in 2020, but the subsequent years witnessed their lights dimming. The Nifty Pharma index underperformed the Nifty 50 benchmark by 14% and 15.5% in 2021 and 2022 respectively, highlighting the challenging terrain.

2. Unraveling the US Generics Landscape

Impact of Regulatory Changes

The US generics market, historically a cash cow for Indian pharma, faced upheavals due to regulatory shifts. Encouragement of heightened competition by the US regulator led to a weakening market. This environment of increased competition exerted pressure on pricing, impacting profitability across the board.

3. Reshaping the Competition Landscape

Consolidation Amidst Competition

The intense competition within the US generics market yielded both winners and losers. Industry consolidation through amalgamations, mergers, and bankruptcies emerged as a significant trend. As Umang Vohra, Managing Director and Global CEO of Cipla, pointed out, "A large number of US companies are either amalgamating, merging, or going bankrupt. That is eliminating a number of players in the system."

4. A Ray of Hope Emerges

Easing Pricing Pressure

The last two quarters witnessed a significant shift in the pricing landscape. Major Indian companies' managements are optimistic about the US generics market's outlook for FY24. This promising trend is attributed to several factors, including better supply chain management, new product launches, and favourable shifts in raw material costs.

5. Diversification: A Strategic Pivot

Adapting to Evolving Dynamics

In response to the turbulent years, key players such as Sun Pharma, Cipla, and Zydus Lifesciences revamped their product mix. The emphasis shifted toward complex generics, speciality drugs, peptides, and injectables – segments that experienced comparatively lower pricing pressures.

6. Riding the Complex Generics Wave

Unlocking High-Margin Opportunities

The revival of the generics segment translates into newfound opportunities. Efforts invested in high-margin complex generics are bearing fruit, further augmenting the resurgence of pharma companies.

7. International Performance Metrics

US Pharma Market Outperforms Indian Market

A noteworthy trend unfolded as the US pharma market outperformed its Indian counterpart in FY23. The revenue from the US generics market for top Indian pharma companies surged by an impressive 16% YoY during this period, surpassing the growth observed in the domestic market.

8. Turning the Tide: Recent Performance Snapshot

US Generics Market Reverses Course

The tide of change continued as the US generics market exhibited a positive turnaround, contrasting with the moderating growth in the Indian market. The first quarter of FY24 witnessed a substantial rise in top pharma companies' US business, while growth within the Indian market slowed down.

9. Fueling Growth with Innovation

New Product Launches and Profitability

Strategic product launches played a pivotal role in bolstering profit margins in recent quarters. Companies are focusing on a multitude of new launches, capitalizing on the initial phase of higher margins before competitors introduce alternatives.

10. India's Footprint in Regulatory Landscape

ANDA Approvals: India's Growing Influence

The regulatory sphere witnessed India's growing prominence. In FY23, India's share in abbreviated new drug application (ANDA) approvals reached a record high of 49%, showcasing the country's increased influence in the US pharmaceutical market.

11. Triumph Amidst Cost Fluctuations

Raw Material and Freight Cost Dynamics

After grappling with escalated costs in 2021 and 2022, the tide has shifted in 2023. Both raw material and freight costs are experiencing a downtrend, reinvigorating profit margins for pharma companies.

12. Navigating Input Price Volatility

Rising Margins Amidst Falling Input Costs

The past year witnessed a drop in input prices for crucial raw materials like para amino phenol and antibiotics. This reduction has translated into both quarterly and yearly margin growth for pharma companies in the first quarter of FY24.

13. Sustaining Momentum: China's Role

API Manufacturers and China's Impact

Despite the overall positive trends, API manufacturers, especially those relying on imports from China, continue to experience margin pressure. As China's influence in India's key starting materials import grows, sustaining margins remains a challenge.

14. The Road Ahead: Balancing Revenue and Growth

Navigating Uncertainty

While revenue visibility in the Indian pharma market remains strong, growth opportunities are marked by uncertainties. The projected steady CAGR of 8-10% over the next five years is driven by factors such as volume growth, price hikes, and new product launches.

15. Strategies Amidst Constraints

Strategic Pricing Amidst Controls

Pharma companies have responded to growth constraints with price hikes. However, comprehensive pricing power is hindered by the National Pharmaceutical Pricing Authority's regulations, which establish ceiling prices for essential drugs.

16. A Landscape of Evolving Constraints

Navigating Regulatory Boundaries

As the number of drugs covered under the National List of Essential Medicines (NLEM) increases steadily, pharma companies are navigating evolving constraints. For non-NLEM products, the potential for price hikes of up to 10% annually offers a strategic avenue.

17. Diversity as the Resilience Pillar

Reducing Risk Through Diversification

Relying solely on the growth of the US business entails risks due to regulatory uncertainties. To mitigate these risks, companies are turning to diversification, leveraging a varied product and geographic mix to thrive in the face of changing dynamics.

18. Concluding Insights

Adaptability: The Key to Sustainable Growth

As the pharma industry traverses diverse cycles, adaptability remains paramount. With a diversified approach and a strategic focus on global markets, Indian pharma companies are well-positioned to not only navigate challenges but also capitalize on emerging opportunities. In the dynamic words of Lakhshay Kataria, CFO of J B Chemicals & Pharmaceuticals, "Diversification is key. Companies with varied product and geo mixes can ride the winds of change in different geos and grow at a faster rate."

Hope you like it! Subscribe for similar weekly articles!

Credit @Tr